The Role of ctDNA/MRD Testing in Cancer: Promise, Practice, and Pitfalls
Circulating tumor DNA (ctDNA) and minimal residual disease (MRD) testing are rapidly transforming the landscape of cancer care. By offering a noninvasive window into the molecular status of a patient’s disease, these technologies are enabling earlier detection of recurrence, more precise monitoring of treatment response, and increasingly personalized therapeutic strategies.
The Role of ctDNA/MRD Testing in Cancer: Promise, Practice, and Pitfalls Read More »